In the latest trading session,, 49.54 million Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares changed hands as the company’s beta touched 0.45. With the company’s most recent per share price at $2.28 changing hands around $0.71 or 45.11% at last look, the market valuation stands at $5.15M. GLMD’s current price is a discount, trading about -943.86% off its 52-week high of $23.80. The share price had its 52-week low at $1.21, which suggests the last value was 46.93% up since then. When we look at Galmed Pharmaceuticals Ltd’s average trading volume, we note the 10-day average is 52650.0 shares, with the 3-month average coming to 867.59K.
Analysts gave the Galmed Pharmaceuticals Ltd (GLMD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended GLMD as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Galmed Pharmaceuticals Ltd’s EPS for the current quarter is expected to be 0.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) trade information
Instantly GLMD is in green as seen in intraday trades today. With action 62.74%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -28.58%, with the 5-day performance at 62.74% in the green. However, in the 30-day time frame, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) is 35.61% up. Looking at the short shares, we see there were 96430.0 shares sold at short interest cover period of 0.04 days.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 45.91%. The 2025 estimates are for Galmed Pharmaceuticals Ltd earnings to increase by 64.49%, but the outlook for the next 5-year period is at 62.35% per year.
GLMD Dividends
Galmed Pharmaceuticals Ltd is expected to release its next quarterly earnings report on 2024-Apr-03.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.90% of Galmed Pharmaceuticals Ltd shares while 2.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 2.12%.
With 1.7 shares estimated at $3521.0 under it, the former controlled 0.08% of total outstanding shares.
